Update on InnomarClinics
InnomarClinics remain open to our patients amidst coronavirus (COVID-19) concerns.
Learn more.

A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers

SpringerLink |

Canada is among the highest spenders on health care in the Organization for Economic Co-operation and Development (OECD). In Canada, public insurance covers only 43% of prescription drug cost, while the remainder is paid by private payers (35%) or patients (out of pocket). In the public sector, provincial/territorial programs and federal direct drug subsidy programs are the main payers.

Fergal Mills, InnomarConsulting, contributes to a comparative review to provide a list of recommendations for revising the Canadian BIA guidelines, with applicability for both public and private plan new drug submissions in Canada.